⚠️ What Buyers Should Watch
The risk-based regulatory shift is a direction, not yet a fully implemented system. Buyers should keep the following in mind:
- No immediate change to existing compliance requirements — manufacturers still need valid WHO-GMP or Schedule M certification, CDSCO licences, and product-specific approvals. The risk-based model adjusts how regulators prioritise inspections, not whether standards apply.
- Monitor CDSCO announcements — as the new framework rolls out, the CDSCO may publish updated inspection schedules, risk-classification criteria, or enforcement priorities. Buyers sourcing from India should track these developments.
- Verify credentials as before — the fundamentals of sourcing safely from India remain unchanged: confirm WHO-GMP certification is current and site-specific, check CDSCO licensing, verify product approvals, and prefer purchasing through verified distribution channels. For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory.
📋 Sources
- Express Pharma — “CDSCO move towards smarter, risk-based regulation to ease doing business for Indian pharma: iPHEX 2026” (September 9, 2026)
- The News Mill — “CDSCO adopts risk-based approach to ease business for Indian pharma” (September 9, 2026)
- India’s News.Net — “CDSCO signals shift towards smarter, risk-based regulation to ease doing business for Indian pharma at iPHEX 2026” (September 9, 2026)
- Pharmabiz.com — “CDSCO to launch first phase of end-to-end digital drug regulatory platform within 18 months: DCGI” (August 3, 2026) — contextual reference for digital regulatory platform timeline
For more information, contact IMSDA at contact@indiamedicine.org.
🔍 What This Means for International Buyers
For buyers of Indian generic medicines — hospitals, government procurement agencies, retail pharmacies, and international distributors — the shift to risk-based regulation has several practical implications:
- Improved quality signal from compliant manufacturers — manufacturers that have invested in robust quality systems and maintain clean compliance records should find it easier to demonstrate regulatory standing. This can be a positive differentiator when evaluating suppliers.
- Stronger scrutiny of problem facilities — the flip side is that facilities with quality issues are more likely to face targeted enforcement. Buyers should stay aware of any CDSCO public notices or regulatory actions against specific manufacturers.
- Closer alignment with global standards — as India’s regulatory approach moves closer to WHO-GMP and international risk-based frameworks, Indian generics may face fewer regulatory barriers in export markets, potentially improving supply reliability for international buyers.
- Digital traceability on the horizon — the DCGI’s ongoing digital platform initiative could eventually make regulatory status, inspection history, and compliance records more accessible — though no specific timeline for buyer-facing tools has been announced.
⚠️ What Buyers Should Watch
The risk-based regulatory shift is a direction, not yet a fully implemented system. Buyers should keep the following in mind:
- No immediate change to existing compliance requirements — manufacturers still need valid WHO-GMP or Schedule M certification, CDSCO licences, and product-specific approvals. The risk-based model adjusts how regulators prioritise inspections, not whether standards apply.
- Monitor CDSCO announcements — as the new framework rolls out, the CDSCO may publish updated inspection schedules, risk-classification criteria, or enforcement priorities. Buyers sourcing from India should track these developments.
- Verify credentials as before — the fundamentals of sourcing safely from India remain unchanged: confirm WHO-GMP certification is current and site-specific, check CDSCO licensing, verify product approvals, and prefer purchasing through verified distribution channels. For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory.
📋 Sources
- Express Pharma — “CDSCO move towards smarter, risk-based regulation to ease doing business for Indian pharma: iPHEX 2026” (September 9, 2026)
- The News Mill — “CDSCO adopts risk-based approach to ease business for Indian pharma” (September 9, 2026)
- India’s News.Net — “CDSCO signals shift towards smarter, risk-based regulation to ease doing business for Indian pharma at iPHEX 2026” (September 9, 2026)
- Pharmabiz.com — “CDSCO to launch first phase of end-to-end digital drug regulatory platform within 18 months: DCGI” (August 3, 2026) — contextual reference for digital regulatory platform timeline
For more information, contact IMSDA at contact@indiamedicine.org.
📋 Why Risk-Based Regulation Matters
The traditional GMP inspection model applies roughly the same checklist and inspection frequency to every manufacturing site, regardless of the risk profile of the products made there. A facility producing simple generic tablets with a decade of clean inspections may receive the same regulatory attention as a facility manufacturing sterile injectables or biologics — even though the latter carries inherently higher patient-safety risk.
A risk-based approach flips this logic:
- Higher-risk products and facilities get more regulatory attention — more frequent inspections, deeper data review, and stricter corrective-action requirements.
- Lower-risk, well-established manufacturers benefit from streamlined processes, faster approvals, and less inspection disruption — freeing up regulator time and industry resources for where they are needed most.
🔍 What This Means for International Buyers
For buyers of Indian generic medicines — hospitals, government procurement agencies, retail pharmacies, and international distributors — the shift to risk-based regulation has several practical implications:
- Improved quality signal from compliant manufacturers — manufacturers that have invested in robust quality systems and maintain clean compliance records should find it easier to demonstrate regulatory standing. This can be a positive differentiator when evaluating suppliers.
- Stronger scrutiny of problem facilities — the flip side is that facilities with quality issues are more likely to face targeted enforcement. Buyers should stay aware of any CDSCO public notices or regulatory actions against specific manufacturers.
- Closer alignment with global standards — as India’s regulatory approach moves closer to WHO-GMP and international risk-based frameworks, Indian generics may face fewer regulatory barriers in export markets, potentially improving supply reliability for international buyers.
- Digital traceability on the horizon — the DCGI’s ongoing digital platform initiative could eventually make regulatory status, inspection history, and compliance records more accessible — though no specific timeline for buyer-facing tools has been announced.
⚠️ What Buyers Should Watch
The risk-based regulatory shift is a direction, not yet a fully implemented system. Buyers should keep the following in mind:
- No immediate change to existing compliance requirements — manufacturers still need valid WHO-GMP or Schedule M certification, CDSCO licences, and product-specific approvals. The risk-based model adjusts how regulators prioritise inspections, not whether standards apply.
- Monitor CDSCO announcements — as the new framework rolls out, the CDSCO may publish updated inspection schedules, risk-classification criteria, or enforcement priorities. Buyers sourcing from India should track these developments.
- Verify credentials as before — the fundamentals of sourcing safely from India remain unchanged: confirm WHO-GMP certification is current and site-specific, check CDSCO licensing, verify product approvals, and prefer purchasing through verified distribution channels. For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory.
📋 Sources
- Express Pharma — “CDSCO move towards smarter, risk-based regulation to ease doing business for Indian pharma: iPHEX 2026” (September 9, 2026)
- The News Mill — “CDSCO adopts risk-based approach to ease business for Indian pharma” (September 9, 2026)
- India’s News.Net — “CDSCO signals shift towards smarter, risk-based regulation to ease doing business for Indian pharma at iPHEX 2026” (September 9, 2026)
- Pharmabiz.com — “CDSCO to launch first phase of end-to-end digital drug regulatory platform within 18 months: DCGI” (August 3, 2026) — contextual reference for digital regulatory platform timeline
For more information, contact IMSDA at contact@indiamedicine.org.
⚕️ What the DCGI Announced
At iPHEX 2026 (September 9–11, 2026), DCGI Dr. Rajesh Bhatia outlined a regulatory roadmap that prioritises risk-proportionate oversight over blanket inspection rules. According to reporting by Express Pharma and The News Mill (September 9, 2026), the new framework aims to:
- Focus inspection resources on high-risk facilities — manufacturers with a history of quality issues, complex formulations, or export-sensitive products will face more frequent and rigorous inspections.
- Reduce routine burdens on low-risk manufacturers — companies with a clean compliance record and stable quality systems may see fewer redundant inspections and faster regulatory clearance.
- Align with international GMP expectations — the risk-based model mirrors approaches already used by regulators in the EU, US, and WHO-prequalified markets, making Indian exports more compatible with global standards.
- Leverage digital tools for monitoring — the DCGI referenced ongoing efforts to digitise drug regulation, including an end-to-end digital regulatory platform expected in phases over the coming months (as previously announced by the DCGI in July–August 2026).
📋 Why Risk-Based Regulation Matters
The traditional GMP inspection model applies roughly the same checklist and inspection frequency to every manufacturing site, regardless of the risk profile of the products made there. A facility producing simple generic tablets with a decade of clean inspections may receive the same regulatory attention as a facility manufacturing sterile injectables or biologics — even though the latter carries inherently higher patient-safety risk.
A risk-based approach flips this logic:
- Higher-risk products and facilities get more regulatory attention — more frequent inspections, deeper data review, and stricter corrective-action requirements.
- Lower-risk, well-established manufacturers benefit from streamlined processes, faster approvals, and less inspection disruption — freeing up regulator time and industry resources for where they are needed most.
🔍 What This Means for International Buyers
For buyers of Indian generic medicines — hospitals, government procurement agencies, retail pharmacies, and international distributors — the shift to risk-based regulation has several practical implications:
- Improved quality signal from compliant manufacturers — manufacturers that have invested in robust quality systems and maintain clean compliance records should find it easier to demonstrate regulatory standing. This can be a positive differentiator when evaluating suppliers.
- Stronger scrutiny of problem facilities — the flip side is that facilities with quality issues are more likely to face targeted enforcement. Buyers should stay aware of any CDSCO public notices or regulatory actions against specific manufacturers.
- Closer alignment with global standards — as India’s regulatory approach moves closer to WHO-GMP and international risk-based frameworks, Indian generics may face fewer regulatory barriers in export markets, potentially improving supply reliability for international buyers.
- Digital traceability on the horizon — the DCGI’s ongoing digital platform initiative could eventually make regulatory status, inspection history, and compliance records more accessible — though no specific timeline for buyer-facing tools has been announced.
⚠️ What Buyers Should Watch
The risk-based regulatory shift is a direction, not yet a fully implemented system. Buyers should keep the following in mind:
- No immediate change to existing compliance requirements — manufacturers still need valid WHO-GMP or Schedule M certification, CDSCO licences, and product-specific approvals. The risk-based model adjusts how regulators prioritise inspections, not whether standards apply.
- Monitor CDSCO announcements — as the new framework rolls out, the CDSCO may publish updated inspection schedules, risk-classification criteria, or enforcement priorities. Buyers sourcing from India should track these developments.
- Verify credentials as before — the fundamentals of sourcing safely from India remain unchanged: confirm WHO-GMP certification is current and site-specific, check CDSCO licensing, verify product approvals, and prefer purchasing through verified distribution channels. For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory.
📋 Sources
- Express Pharma — “CDSCO move towards smarter, risk-based regulation to ease doing business for Indian pharma: iPHEX 2026” (September 9, 2026)
- The News Mill — “CDSCO adopts risk-based approach to ease business for Indian pharma” (September 9, 2026)
- India’s News.Net — “CDSCO signals shift towards smarter, risk-based regulation to ease doing business for Indian pharma at iPHEX 2026” (September 9, 2026)
- Pharmabiz.com — “CDSCO to launch first phase of end-to-end digital drug regulatory platform within 18 months: DCGI” (August 3, 2026) — contextual reference for digital regulatory platform timeline
For more information, contact IMSDA at contact@indiamedicine.org.
India’s drug regulator is signalling a major shift in how it oversees the pharmaceutical industry — moving from a uniform, checklist-based inspection model toward a smarter, risk-based approach that could ease compliance burdens for manufacturers while tightening scrutiny where it matters most. The announcement came from the Drug Controller General of India (DCGI) at the India Pharma & Healthcare Expo (iPHEX 2026) in September 2026, and it has direct implications for international buyers of Indian generic medicines.
⚕️ What the DCGI Announced
At iPHEX 2026 (September 9–11, 2026), DCGI Dr. Rajesh Bhatia outlined a regulatory roadmap that prioritises risk-proportionate oversight over blanket inspection rules. According to reporting by Express Pharma and The News Mill (September 9, 2026), the new framework aims to:
- Focus inspection resources on high-risk facilities — manufacturers with a history of quality issues, complex formulations, or export-sensitive products will face more frequent and rigorous inspections.
- Reduce routine burdens on low-risk manufacturers — companies with a clean compliance record and stable quality systems may see fewer redundant inspections and faster regulatory clearance.
- Align with international GMP expectations — the risk-based model mirrors approaches already used by regulators in the EU, US, and WHO-prequalified markets, making Indian exports more compatible with global standards.
- Leverage digital tools for monitoring — the DCGI referenced ongoing efforts to digitise drug regulation, including an end-to-end digital regulatory platform expected in phases over the coming months (as previously announced by the DCGI in July–August 2026).
📋 Why Risk-Based Regulation Matters
The traditional GMP inspection model applies roughly the same checklist and inspection frequency to every manufacturing site, regardless of the risk profile of the products made there. A facility producing simple generic tablets with a decade of clean inspections may receive the same regulatory attention as a facility manufacturing sterile injectables or biologics — even though the latter carries inherently higher patient-safety risk.
A risk-based approach flips this logic:
- Higher-risk products and facilities get more regulatory attention — more frequent inspections, deeper data review, and stricter corrective-action requirements.
- Lower-risk, well-established manufacturers benefit from streamlined processes, faster approvals, and less inspection disruption — freeing up regulator time and industry resources for where they are needed most.
🔍 What This Means for International Buyers
For buyers of Indian generic medicines — hospitals, government procurement agencies, retail pharmacies, and international distributors — the shift to risk-based regulation has several practical implications:
- Improved quality signal from compliant manufacturers — manufacturers that have invested in robust quality systems and maintain clean compliance records should find it easier to demonstrate regulatory standing. This can be a positive differentiator when evaluating suppliers.
- Stronger scrutiny of problem facilities — the flip side is that facilities with quality issues are more likely to face targeted enforcement. Buyers should stay aware of any CDSCO public notices or regulatory actions against specific manufacturers.
- Closer alignment with global standards — as India’s regulatory approach moves closer to WHO-GMP and international risk-based frameworks, Indian generics may face fewer regulatory barriers in export markets, potentially improving supply reliability for international buyers.
- Digital traceability on the horizon — the DCGI’s ongoing digital platform initiative could eventually make regulatory status, inspection history, and compliance records more accessible — though no specific timeline for buyer-facing tools has been announced.
⚠️ What Buyers Should Watch
The risk-based regulatory shift is a direction, not yet a fully implemented system. Buyers should keep the following in mind:
- No immediate change to existing compliance requirements — manufacturers still need valid WHO-GMP or Schedule M certification, CDSCO licences, and product-specific approvals. The risk-based model adjusts how regulators prioritise inspections, not whether standards apply.
- Monitor CDSCO announcements — as the new framework rolls out, the CDSCO may publish updated inspection schedules, risk-classification criteria, or enforcement priorities. Buyers sourcing from India should track these developments.
- Verify credentials as before — the fundamentals of sourcing safely from India remain unchanged: confirm WHO-GMP certification is current and site-specific, check CDSCO licensing, verify product approvals, and prefer purchasing through verified distribution channels. For a list of verified and reliable pharmaceutical distributors, refer to the IMSDA’s verified member directory.
📋 Sources
- Express Pharma — “CDSCO move towards smarter, risk-based regulation to ease doing business for Indian pharma: iPHEX 2026” (September 9, 2026)
- The News Mill — “CDSCO adopts risk-based approach to ease business for Indian pharma” (September 9, 2026)
- India’s News.Net — “CDSCO signals shift towards smarter, risk-based regulation to ease doing business for Indian pharma at iPHEX 2026” (September 9, 2026)
- Pharmabiz.com — “CDSCO to launch first phase of end-to-end digital drug regulatory platform within 18 months: DCGI” (August 3, 2026) — contextual reference for digital regulatory platform timeline
For more information, contact IMSDA at contact@indiamedicine.org.